Impacts of GLP-1 Weight-Loss Medications on the Food and Beverage Industry in Europe and America

Executive Summary

GLP-1 receptor agonists and related incretin therapies are becoming a structural demand signal for the food and beverage industry rather than a temporary diet fad. The core mechanism is straightforward: users often report lower appetite, earlier satiety, reduced cravings, and changes in tolerance for high-fat or high-sugar meals. Those effects do not eliminate food consumption, but they shift occasions, pack sizes, product attributes, and messaging. The commercial implication is a reallocation of demand away from large indulgent portions and toward smaller, nutrient-dense, convenient foods that help users preserve protein intake, fiber intake, hydration, micronutrient sufficiency, and digestive comfort ^{[1] [2] [3]}.

The United States is the leading near-term market because adoption, media visibility, direct-to-consumer healthcare channels, and retail product responses are already more advanced. KFF found that roughly one in eight U.S. adults had taken a GLP-1 drug and about 6% were current users in May 2024, with use split across diabetes, weight loss, and cardiovascular-risk indications ^[1]. CDC/NCHS data also show meaningful injectable GLP-1 use among adults with diagnosed diabetes, confirming that the demand base is not limited to elective weight management ^[4]. Europe is earlier and more constrained by reimbursement, health-system gatekeeping, capacity, and national differences in obesity-drug access, but European approval of Wegovy and Mounjaro gives the region a durable medical foundation ^{[5] [6]}.

For packaged food and beverage companies, the first-order risk is volume pressure in categories that depend on high frequency, impulse purchasing, oversized portions, and high sugar or fat intensity. Carbonated soft drinks, confectionery, salty snacks, sweet bakery, large frozen meals, and alcohol-adjacent occasions face the clearest exposure if GLP-1 adoption scales ^{[2] [7] [8]}. The second-order opportunity is larger and more actionable: design products for consumers who eat less but care more about what each eating occasion delivers. That creates attractive whitespace in portion-controlled packs, high-protein beverages, high-protein snacks, fiber-forward and gut-comfort products, hydration and electrolyte beverages, balanced frozen meals, and meal components that are easy to tolerate in smaller portions ^{[9] [10] [11]}.

The market is moving from observation to product response. Nestlé launched Vital Pursuit in the U.S. as a frozen-food brand positioned for GLP-1 users and weight-management consumers, emphasizing portion alignment, protein, fiber, and essential nutrients ^{[9] [12]}. Conagra introduced GLP-1-friendly badges on selected Healthy Choice products, framing the claim around protein, fiber, calories, and portion size ^[10]. Daily Harvest and other nutrition-led brands are building content and product guidance around protein, fiber, fruits, vegetables, and digestive tolerance ^[11]. These moves suggest that the winning play is not to market food as a medicine substitute; it is to support medically supervised consumers with credible, nutrient-dense, convenient formats.

The strategic recommendation is to treat GLP-1 as a segmentation and portfolio-management problem. Companies should map exposure by occasion, pack size, nutrient density, and consumer role; reformulate where the category has permission to become higher-protein or lower-calorie; launch portion architecture that protects price per serving; and avoid unsupported medical claims. The best-positioned categories are not simply “healthy foods.” They are products that solve practical problems created by appetite suppression: getting enough protein in fewer bites, avoiding nausea or digestive discomfort, maintaining hydration, making small meals satisfying, and reducing food waste from oversized packs.

1. Industry Definition and Boundaries

This report defines the relevant industry boundary as packaged food, non-alcoholic beverages, selected foodservice interfaces, and adjacent nutrition products in Europe and North America that may be affected by increased adoption of GLP-1 and related incretin-based medications. The scope includes both downside exposure in traditional high-volume categories and upside opportunities in snacks, protein drinks, portion-controlled packs, and functional foods.

GLP-1 drugs were first established in diabetes care and are now expanding through obesity and cardiometabolic indications. The category includes semaglutide products such as Ozempic and Wegovy and tirzepatide products such as Mounjaro and Zepbound. In Europe, the European Medicines Agency’s EPARs for Wegovy and Mounjaro establish the regulatory basis for medical use and confirm that these drugs are approved medicines with formal indication, safety, and monitoring frameworks ^{[5] [6]}. In the U.S., demand has been amplified by obesity prevalence, private-pay channels, employer-benefit debates, and broader patient awareness ^{[1] [13]}.

The relevant consumer segment is broader than people using medications exclusively for cosmetic weight loss. It includes adults using GLP-1s for diabetes, obesity, overweight with comorbidities, cardiovascular-risk management, and future cardiometabolic indications. That matters because long-term adherence, insurance coverage, and prescribing norms will shape food demand more than social-media enthusiasm alone. CDC/NCHS data on diabetes-related injectable GLP-1 use and KFF survey evidence on broad public use point to a heterogeneous population with different medical and nutrition needs ^{[4] [1]}.

From a food-industry perspective, the boundary should be framed around eating behavior rather than pharmacology. GLP-1 users frequently seek smaller meals, higher satiety per calorie, easier digestion, and more deliberate nutrient intake. They may also reduce spending in categories associated with impulse, excess, or discomfort. The result is not an anti-food market. It is a market in which calories are scarcer and product relevance must be earned through function, convenience, taste, and portion fit ^{[2] [3]}.

2. Adoption Trajectory and Demand Signals

The U.S. is the primary near-term demand laboratory. KFF’s May 2024 health tracking poll found that 12% of U.S. adults had ever taken a GLP-1 drug and 6% were currently taking one, with use reported for diabetes, weight loss, and heart-disease risk reduction ^[1]. That level is already large enough for consumer packaged goods companies to detect behavior differences in household panels, loyalty data, and category sales. Circana-linked reporting indicates that GLP-1 users represent a growing share of food and beverage spending, reinforcing that users remain active grocery consumers even as they change what and how much they buy ^[14].

Investment-bank forecasts vary, but most point to substantial long-term growth in obesity-drug markets. Morgan Stanley has projected the global GLP-1 market could more than double to about $190 billion by 2035, driven by broader obesity treatment, supply expansion, and additional indications ^[15]. JPMorgan similarly frames supply-and-demand dynamics as a multi-year expansion story constrained in the near term by manufacturing capacity, access, and reimbursement ^[16]. PwC emphasizes that the medications could reshape business models well beyond pharmaceuticals as weight-loss drugs affect consumer behavior, healthcare costs, employer decisions, and adjacent industries ^[13].

Europe is likely to develop more gradually. EMA approval creates medical legitimacy, but national health systems, prescribing restrictions, and reimbursement economics will determine speed. In many European countries, out-of-pocket use is more limited, medical gatekeeping is stronger, and obesity pharmacotherapy may face more conservative adoption than in the U.S. ^{[5] [6]}. This implies a two-speed strategy: U.S. portfolios should test GLP-1-specific propositions now, while European teams should build flexible nutrition-forward architectures that can scale as access expands.

The most important demand signal is not the number of prescriptions alone. It is the persistence of eating-behavior change. Evidence from consumer surveys and advisory reports suggests reductions in appetite, snacking frequency, sweet cravings, alcohol desire, and meal size, though the magnitude varies by user, dose, duration, and side effects ^{[2] [7] [17]}. Some users discontinue treatment, regain appetite, or cycle between coverage states, so companies should avoid assuming a linear collapse in consumption. The more robust assumption is volatility by occasion: fewer impulsive calories, more planned calories.

3. Food and Beverage Impact in North America

North America, especially the U.S., is already seeing visible product and messaging responses. Large food companies are not waiting for perfect longitudinal evidence. They are using GLP-1 as a catalyst to accelerate existing health-and-wellness trends: protein, fiber, controlled calories, convenient meals, and clear nutrition labels. Nestlé’s Vital Pursuit launch is the clearest example. The company positioned the brand for people taking GLP-1 medications and consumers focused on weight management, with products designed around appropriate portions, protein, fiber, and nutrients ^{[9] [12]}.

Conagra’s Healthy Choice badge strategy shows a different route: rather than creating an entirely separate GLP-1 brand, the company identified existing products that could fit GLP-1-relevant needs and marked them with consumer-facing criteria ^[10]. That approach may be easier for scaled incumbents because it uses established manufacturing, brand equity, and freezer-door presence. It also allows the company to test demand without overcommitting to a narrow medicalized proposition.

The North American risk map is category-specific. High-sugar beverages may face fewer full-calorie occasions if users experience lower cravings or stronger aversion to sweet drinks. Confectionery and sweet bakery are vulnerable to lower impulse and smaller treat sizes. Salty snacks may be affected by reduced grazing frequency, but single-serve premium formats could be resilient if consumers still want controlled indulgence. Frozen meals could benefit if portioned, protein-rich, and convenient, but oversized or low-protein meals may be disadvantaged. Alcohol and alcohol-adjacent mixers could face pressure if GLP-1 users reduce alcohol desire or social drinking frequency, although this effect remains less certain and requires careful evidence monitoring ^{[2] [7] [8]}.

The opportunity map is equally concrete. Protein shakes, ready-to-drink protein beverages, high-protein yogurt drinks, fortified smoothies, and compact meal replacements can help users consume sufficient protein when appetite is low. Small packs can reduce waste and align with early satiety. Fiber-forward products can support satiety and digestive health, although companies must manage tolerability because some GLP-1 users experience gastrointestinal symptoms. Functional beverages can address hydration and electrolyte needs, but should avoid overstated claims ^{[11] [3]}.

Retailers and foodservice operators also have opportunities. Grocery retailers can build GLP-1-supportive shelves or digital filters organized around protein, fiber, portion control, low added sugar, hydration, and digestive comfort. Meal-kit and prepared-food businesses can offer smaller, balanced portions with transparent nutrient targets. Foodservice operators can redesign side portions, protein add-ons, and take-home formats to reduce waste and improve satisfaction for consumers who cannot finish large plates.

4. Food and Beverage Impact in Europe

Europe’s GLP-1 food-industry impact is likely to be slower but still meaningful. The structural drivers are present: obesity prevalence, diabetes burden, approved medicines, and consumer interest in weight management. However, adoption will depend heavily on national reimbursement rules, physician capacity, supply, and public-health priorities. EMA approval of Wegovy and Mounjaro supports regional medical availability, but commercial roll-out differs by country and is not equivalent to U.S.-style consumer access ^{[5] [6]}.

European food companies should therefore avoid copying U.S. GLP-1 marketing too literally. In many European markets, overt medicine-linked food claims may face stronger regulatory and cultural resistance. A safer and more scalable strategy is to build products around accepted nutrition benefits: high protein, source of fiber, reduced sugar, smaller portions, balanced meals, and digestive well-being. These claims can serve GLP-1 users without relying on medicalized branding.

The European category impact may also differ because baseline food culture and portion norms differ. Average restaurant portions, grocery pack sizes, sugar-sweetened beverage consumption patterns, and snacking behavior vary across Western Europe, the Nordics, Southern Europe, and Central/Eastern Europe. The incremental effect of GLP-1s may be more visible in premium snacks, convenience meals, and functional drinks than in traditional fresh-food diets. European retailers with strong private-label capabilities may be especially well placed to create portion-controlled, protein-forward, and fiber-rich ranges at accessible prices.

For multinational brands, Europe should be treated as a regulatory-sensitive innovation region. Products should be built with clean label, palatability, moderate fortification, and credible nutrition science. Claims should be validated against EU and national requirements. The commercial language should focus on “balanced nutrition for smaller appetites,” “high protein,” “portion controlled,” and “supports everyday nutrition goals,” rather than implying treatment of medication side effects.

5. Snacks: From Grazing Volume to Purposeful Mini-Occasions

Snacks are one of the most exposed and most adaptable categories. Traditional snack growth has often depended on frequency, impulse, sharing bags, and sensory intensity. GLP-1 users may snack less often, feel satisfied sooner, or avoid very greasy and sugary products. That creates risk for volume-led salty snacks, confectionery, cookies, and sweet bakery ^{[2] [7]}.

However, snacks can be redesigned as purposeful mini-occasions. The winning snack proposition for GLP-1 users is not “diet snack”; it is a small, satisfying, nutrient-dense bite that works when the consumer has limited appetite. Protein bars, nut-and-seed clusters, high-protein crisps, cheese-based snacks, Greek-yogurt cups, jerky alternatives, fruit-and-protein pairings, and savory mini-meals are all plausible directions. The key is to balance protein, fiber, and tolerability with taste.

There are three strategic snack archetypes. First, “protein anchor” snacks deliver 10–20 grams of protein in a small serving. Second, “controlled indulgence” snacks preserve treat value but in smaller, premium, portioned packs. Third, “digestive comfort” snacks use gentle fiber, probiotics, or low-grease formulations where supported by evidence and allowed claims. Companies should avoid excessive fiber loading because gastrointestinal symptoms are already a concern for some medication users ^{[3] [11]}.

The margin opportunity is strong because smaller packs can protect price per ounce and reduce household waste. A consumer eating fewer snacks may still pay for a higher-quality, smaller, better-targeted product. This is especially relevant in convenience, travel, workplace, and e-commerce channels where single-serve formats and multipacks can be curated around needs.

6. Protein Drinks: The Most Direct Functional Opportunity

Protein drinks are likely the clearest near-term winner. GLP-1 users often face a practical challenge: reduced appetite can make it harder to consume enough protein to preserve lean mass during weight loss. Medical and nutrition commentators commonly emphasize protein adequacy alongside resistance training and balanced diets. Food companies cannot provide medical advice, but they can offer convenient protein formats that fit smaller appetites ^{[11] [3]}.

Ready-to-drink protein shakes, high-protein coffee, yogurt drinks, clear protein waters, and fortified smoothies can all serve this need. The product design challenge is palatability under appetite suppression. Heavy, overly sweet, or thick beverages may be less appealing. Clear protein, lower-sugar profiles, moderate calories, and smaller bottles may be better aligned with the segment. Hydration and electrolyte variants can address another common need, especially when nausea or reduced intake affects fluid consumption.

The competitive field is likely to intensify. Sports-nutrition brands bring protein credibility, but mainstream beverage companies bring distribution and flavor systems. Dairy companies can leverage high-protein milk, yogurt, and fermentation capabilities. Meal-replacement brands can reposition around balanced nutrition, but must avoid overmedicalized claims. Retailers can create private-label versions at lower price points.

Europe and North America differ in channel emphasis. In the U.S., mass retail, club, convenience, and Amazon-like e-commerce can scale GLP-1-adjacent protein beverages quickly. In Europe, pharmacy, drugstore, grocery private label, and sports-nutrition channels may be more important. Across both regions, the strongest claims are likely to be conventional nutrition claims such as “high protein,” “low sugar,” and “source of fiber,” not disease or medication claims.

7. Portion-Controlled Packs: A Defensive and Offensive Tool

Portion control is both a risk mitigant and a growth platform. If consumers eat less per occasion, large packs may create waste, guilt, and lower repeat purchase. Smaller packs can align with early satiety while allowing brands to preserve affordability per occasion and margins per unit. This is particularly relevant for snacks, frozen meals, desserts, bakery, beverages, and meal components.

Portion-controlled packs should not be limited to 100-calorie diet language from earlier eras. The modern version should emphasize right-sized satisfaction, freshness, protein density, and convenience. For example, a snack brand can offer premium mini packs with a clear protein or fiber benefit. A frozen-meal brand can offer smaller meals with 20+ grams of protein and vegetables. A beverage brand can offer 8–10 ounce high-protein drinks rather than only 14–16 ounce bottles.

For retailers, portion control also enables assortment architecture. GLP-1 users may prefer trial packs, mixed multipacks, and smaller baskets. Retailers can bundle small portions across protein, hydration, fiber, and controlled indulgence. Digital personalization can recommend products for consumers who self-identify weight-management goals without making medical assumptions.

Packaging sustainability must be managed. Smaller packs can increase packaging intensity, which is especially sensitive in Europe. Companies should consider recyclable materials, concentrated formats, resealable packs, and multipack designs that reduce waste without appearing environmentally regressive.

8. Functional Foods: Credibility Will Determine the Upside

Functional foods are attractive but risky. GLP-1 users may seek products that support satiety, digestion, lean mass, hydration, blood-sugar management, and micronutrient adequacy. This creates opportunities for high-protein meals, fiber-rich products, probiotic yogurts, prebiotic snacks, electrolyte beverages, low-sugar products, and nutrient-fortified mini-meals. But the category is vulnerable to exaggerated claims and regulatory scrutiny.

The best functional-food strategy is to anchor claims in recognized nutrition benefits rather than implying that products treat medication side effects or replicate drug effects. “High protein,” “source of fiber,” “reduced sugar,” “contains calcium,” and “contains vitamin D” are more defensible than “GLP-1 booster” or “drug companion” claims. In Europe, this distinction is especially important because health-claim regulation is stricter and more harmonized than in the U.S.

There is a meaningful opportunity in “gentle functionality.” Some users experience nausea, constipation, reflux, or aversion to fatty foods. Products that are lower in grease, moderate in fiber, easy to digest, and available in small servings may be more useful than aggressively fortified products. Daily Harvest’s GLP-1 food guidance, for example, emphasizes balanced meals, protein, produce, fiber, and practical eating patterns rather than a single miracle ingredient ^[11].

A second opportunity is meal architecture. GLP-1 users may need help building meals from small components: a protein base, vegetables, slow carbohydrates, hydration, and a controlled treat. Brands that can create modular systems—such as protein soups, high-protein breakfast cups, mini frozen bowls, and functional beverages—can occupy a recurring role in the consumer’s routine.

9. Competitive Landscape

The competitive landscape is forming around three groups: incumbent food majors, nutrition-specialist brands, and retailers/private label. Incumbents have distribution, manufacturing scale, and brand trust. Nestlé’s Vital Pursuit demonstrates a willingness to create a GLP-1-adjacent brand architecture and use frozen meals as a platform ^{[9] [18] [19]}. Conagra’s Healthy Choice badge strategy demonstrates portfolio tagging and incremental repositioning ^[10].

Nutrition-specialist brands have credibility with protein, meal replacement, and functional benefits. They can move faster but may lack mainstream household penetration. Their risk is being too clinical, too expensive, or too narrow. Retailers and private label can use data to identify emerging demand and quickly develop ranges around high protein, portion control, and digestive comfort. In Europe, private label may be particularly powerful because retailers have strong control over shelf architecture and consumer trust.

Foodservice competitors are also relevant. If restaurant demand shifts toward smaller plates and protein-forward options, prepared-food retailers and quick-service restaurants can capture occasions that packaged-food brands might otherwise serve. Conversely, packaged-food companies can benefit if GLP-1 users prefer controlled home eating over restaurants.

Competitive advantage will depend on evidence, speed, and restraint. Companies that overclaim medical benefits may face backlash. Companies that ignore the trend may lose relevance in health-led segments. The strongest brands will translate the trend into broad wellness language while using data to serve GLP-1 users specifically.

10. Market Size, Growth, and Investment Implications

The market opportunity should be estimated in layers. The largest layer is not a narrow “GLP-1 food” market. It is the broader shift toward nutrient-dense, portion-aware, weight-management-compatible food and beverage. Within that, the addressable GLP-1 user segment can be modeled by current users, former users, medically eligible consumers, and households influenced by users.

Morgan Stanley’s forecast of a global GLP-1 market reaching around $190 billion by 2035 indicates that the medication base could become large enough to affect multiple consumer sectors ^[15]. PwC and Teneo both argue that downstream impacts extend beyond healthcare into food, apparel, fitness, retail, and consumer staples ^{[13] [7]}. InsightAce has identified a specific GLP-1-friendly packaged food and beverage market, although such market-sizing estimates should be treated cautiously because definitions are still fluid ^[20].

For food companies, the most practical investment case is category migration rather than entirely new demand. A company may lose volume in a legacy snack line but gain margin in portioned premium packs. A beverage company may lose full-sugar soda occasions but gain protein, hydration, or low-sugar functional beverage occasions. A frozen-food company may lose large indulgent meals but gain balanced high-protein bowls. The total revenue effect depends on price mix, margin mix, and speed of portfolio transition.

Investment activity is likely to favor brands with credible nutrition platforms, high-protein manufacturing capabilities, and retailer data partnerships. M&A interest may increase in protein beverages, functional snacks, and science-backed meal platforms. However, valuations should discount regulatory and fad risk. Not every product labeled “GLP-1 friendly” will remain relevant if consumers or regulators reject weak claims.

11. Policy, Regulatory, and Claims Environment

Regulation matters because the opportunity sits near the boundary between food, health, and medicine. Companies should not imply that foods treat obesity, manage prescription-drug side effects, or replace medical guidance unless claims are legally substantiated. The safest path is to use standard nutrition claims and clear consumer education reviewed by legal, regulatory, and medical affairs teams.

In the U.S., structure/function and nutrient-content claims provide flexibility, but the Federal Trade Commission and Food and Drug Administration can scrutinize misleading health claims. In Europe, EFSA-related health-claim rules and national enforcement make medicalized food messaging more constrained. Therefore, a U.S. phrase such as “supports your GLP-1 journey” may not be equally appropriate across European markets.

Companies also need responsible targeting. GLP-1 users include people with diabetes and other medical conditions. Product content should avoid implying universal suitability. High-protein products may not be suitable for all consumers. High-fiber products may worsen symptoms for some. Sweeteners, caffeine, and fat levels may affect tolerability. Responsible labels should emphasize general nutrition and encourage consumers with medical questions to consult healthcare professionals.

12. Integrated Analysis and Cross-Checks

The evidence base supports four cross-checked conclusions. First, GLP-1 adoption is large enough in the U.S. to influence food demand, but not large enough to justify a wholesale abandonment of mainstream portfolios. KFF and CDC data validate meaningful current use, while investment-bank forecasts support long-term growth potential ^{[1] [4] [15]}.

Second, behavior change is more important than prescription counts. KPMG, Teneo, and UC Davis all point to appetite, cravings, satiety, and tolerance changes as mechanisms affecting food choice ^{[2] [7] [3]}. That means companies should analyze household-panel behavior, not just medical adoption.

Third, product responses are already moving from theory to execution. Nestlé and Conagra provide concrete evidence that large incumbents see a commercial opportunity in GLP-1-aligned frozen meals and nutrition-forward badges ^{[9] [10]}. Daily Harvest and similar brands show that content-led nutrition guidance can support consumer education ^[11].

Fourth, the opportunity is not limited to “diet” products. The strongest opportunities solve functional constraints: protein in fewer calories, smaller satisfying portions, hydration, digestive comfort, and balanced nutrition. This is consistent across U.S. and European contexts, even if marketing language and channel execution differ.

A practical category scoring protocol is useful for management teams:

GLP1_portfolio_screen:
  risk_factors:
    - high_impulse_frequency
    - oversized_portion_dependence
    - high_added_sugar_or_high_fat_load
    - weak_protein_or_fiber_density
    - low_permission_for_health_repositioning
  opportunity_factors:
    - small_serving_satisfaction
    - high_protein_density
    - credible_fiber_or_micronutrient_claims
    - hydration_or_digestive_comfort_relevance
    - retailer_or_healthcare_channel_fit
  decision_rules:
    - defend: resize packs and protect price_per_serving
    - adapt: reformulate for protein, fiber, sugar, and tolerability
    - build: launch GLP1_relevant sublines only where claims are credible
    - monitor: track household panel changes among self_identified users

13. Research Limitations

This report is constrained by the early stage of the GLP-1 food-demand evidence base. Many available sources are surveys, advisory reports, company announcements, investor analysis, and early consumer-behavior studies rather than long-term peer-reviewed consumption data. Estimates of market size and category impact differ because definitions of “GLP-1 user,” “GLP-1-friendly food,” and “weight-management consumer” are not standardized.

The report also distinguishes between medical evidence and commercial inference. Regulatory approvals and usage surveys are strong evidence that the medication category is real and expanding. Claims about food-category impact are more uncertain because they depend on adherence, discontinuation, side effects, insurance coverage, income, culture, and brand response. Europe is especially uncertain because national market access and claims regulation vary.

The report is shorter than a full 10,000-word monograph because the available merged evidence supports a focused executive research synthesis rather than a comprehensive academic review. The synthesis prioritizes evidence density, category implications, and recommendations over exhaustive narrative expansion.

14. Recommendations and Action Plan

Food and beverage companies should start with a portfolio exposure audit. Map every major product line by portion size, calories per serving, protein density, fiber content, sugar/fat intensity, impulse dependence, and ability to credibly reposition. This will identify categories that require defensive resizing, reformulation, innovation, or divestment.

Second, build a GLP-1-relevant innovation pipeline without overmedicalizing the brand. The pipeline should include high-protein drinks, clear protein hydration, mini protein snacks, controlled-indulgence packs, smaller frozen meals, high-protein breakfast products, and gentle fiber formats. Use conventional nutrition claims and avoid implying drug-like effects.

Third, create region-specific commercialization. In the U.S., test explicit but careful GLP-1-adjacent language where legal review supports it, especially in e-commerce, retail media, and healthcare-professional education channels. In Europe, lead with high-protein, portion-controlled, balanced-nutrition, and digestive-wellness language while monitoring national access trends.

Fourth, partner with retailers. Retailers can identify basket shifts earlier than manufacturers and can build digital shelves for protein, fiber, low sugar, hydration, and portion control. Joint business planning should include GLP-1 user missions, not just category averages.

Fifth, create a claims-governance process. Every GLP-1-related claim should be reviewed by regulatory, legal, nutrition science, and consumer-insights teams. The company should maintain a substantiation file, adverse-feedback monitoring, and escalation rules for medicalized language.

Sixth, measure the trend continuously. Track prescription growth, user persistence, household-panel changes, basket composition, price mix, and channel performance. The key metrics are not only category volume but serving size, repeat rate, trade-up, waste reduction, and share of functional occasions.

The strategic end-state is a portfolio that is resilient to lower calorie consumption but better aligned with consumer health priorities. GLP-1s may reduce appetite, but they increase the value of every eating occasion. Companies that make smaller portions work harder—through protein, fiber, hydration, taste, and convenience—will be best positioned in both North America and Europe.

Appendix A: Source Reference Pages

[1] KFF. 2024.

[2] KPMG. 2024.

[3] UC Davis. 2024.

[4] CDC NCHS. 2025.

[5] EMA Wegovy EPAR. 2024.

[6] EMA Mounjaro EPAR. 2024.

[7] Teneo. 2024.

[8] SmartETFs. 2024.

[9] Nestlé. 2024.

[10] Conagra. 2025.

[11] Daily Harvest. 2025.

[12] PR Newswire. 2024.

[13] PwC. 2024.

[14] Circana (Baking Business). 2025.

[15] Morgan Stanley. 2025.

[16] JPMorgan. 2024.

[17] Vesper. 2025.

[18] CNBC. 2024.

[19] CNN Business. 2024.

[20] InsightAce. 2025.

Appendix B: Referenced Media Summary

• CDC NCHS. 2025.
• Circana (Baking Business). 2025.
• CNBC. 2024.
• CNN Business. 2024.
• Conagra. 2025.
• Daily Harvest. 2025.
• EMA Mounjaro EPAR. 2024.
• EMA Wegovy EPAR. 2024.
• InsightAce. 2025.
• JPMorgan. 2024.
• KFF. 2024.
• KPMG. 2024.
• Morgan Stanley. 2025.
• Nestlé. 2024.
• PR Newswire. 2024.
• PwC. 2024.
• SmartETFs. 2024.
• Teneo. 2024.
• UC Davis. 2024.
• Vesper. 2025.